PharmExtracta at CPHI 2025: Two New Launches and a World of Collaboration Opportunities

PharmExtracta will once again be part of CPHI 2025 — the global meeting point for pharmaceutical innovation and partnership building.
As every year, we look forward to connecting with companies and professionals who share our passion for science-driven health solutions.
A pharmaceutical company by vocation, PharmExtracta applies the same rigorous standards of drug development to its portfolio of food supplements — from precision probiotics to advanced botanicals.

PharmExtracta presents two new 2025 launches at CPHI Frankfurt

PharmExtracta continues its journey of innovation in precision probiotics, introducing two new products to the international market: Colipral® and Brevicillin® Drops.

Both represent the next generation of science-backed, strain-specific probiotics—developed to support intestinal balance and overall health across different age groups.

🧬 Colipral® Capsules – A new generation E. coli-based probiotic

Colipral® is a breakthrough in probiotic innovation, developed with Escherichia coli 5C (ECP24®), a thoroughly characterized, genomically safe strain of human origin.
Each enteric-coated capsule delivers 1×10⁹ CFU, ensuring full intestinal release.

coli 5C (ECP24®) demonstrates:

Strong adhesion to colon cells (84%)
Anti-inflammatory and immunomodulatory effects via IL-10 stimulation
Cross-feeding activity, boosting acetate and butyrate production
Competitive inhibition against pathogenic coli

These features translate into targeted clinical benefits, such as:

Supporting remission in ulcerative colitis
Helping prevent recurrent prostatitis and cystitis
Promoting post-colonoscopy intestinal balance

With a certified genomic safety profile and EFSA-compliant antibiotic resistance, Colipral® redefines the concept of precision bacterial care.

👶 Brevicillin® Drops – The child-friendly precision probiotic

Following the success of Brevicillin® Stick packs, PharmExtracta now introduces Brevicillin® Drops, designed specifically for the youngest patients.
Both formats share the same Bifidobacterium breve PRL2020 strain – the only bacterial strain proven resistant to Amoxicillin and Amoxicillin/Clavulanic acid, enabling safe co-administration during antibiotic therapy.

What’s new:

Formulation “tailored for children”, easy to dose and suitable even for newborns
Oil-based suspension – ensures room-temperature stability throughout the product’s shelf life
5 billion live cells per dose (5 drops)

Clinical data confirm that co-administration of Brevicillin® significantly:

Reduces antibiotic-associated diarrhea by 70% (8.5% vs 28%)
Preserves bifidobacterial populations, preventing dysbiosis
Limits Proteobacteria overgrowth, including pathogenic coli

With its dual-format approach, Brevicillin® offers tailored protection across all ages.

☕ Join us at CPHI Frankfurt 2025

Let’s meet in person to discuss innovation opportunities and explore how these two newly launched probiotics can fit your market needs.

Not into probiotics? We’re about much more than that! At PharmExtracta, we apply the same rigorous pharmaceutical standards to our entire portfolio of food supplements, ranging from precision probiotics to advanced botanicals, through to biomolecular supplements that provide targeted support for conditions driven by molecular imbalances.

👉 Explore the full PharmExtracta Product Portfolio

And most of all, come to visit us at our stand — we’ll be delighted to welcome you and share an authentic Italian coffee together!
📍 Stand 3.0K6 – CPHI Frankfurt 2025
📅 October 28–30, 2025